The antiserum was produced against synthesized peptide derived from human IkappaB-beta around the phosphorylation site of Ser23. AA range:8-57

Phospho-IκB-β (S23) Polyclonal Antibody detects endogenous levels of IκB-β protein only when phosphorylated at S23.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):LGsLG

NFKBIB

NF-kappa-B inhibitor beta

NFKBIB ;
IKBB ;
TRIP9 ;
NF-kappa-B inhibitor beta ;
NF-kappa-BIB ;
I-kappa-B-beta ;
IkB-B ;
IkB-beta ;
IkappaBbeta ;
Thyroid receptor-interacting protein 9 ;
TR-interacting protein 9 ;
TRIP-9

The protein encoded by this gene belongs to the NF-kappa-B inhibitor family, which inhibit NF-kappa-B by complexing with, and trapping it in the cytoplasm. Phosphorylation of serine residues on these proteins by kinases marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B, which translocates to the nucleus to function as a transcription factor. Alternatively spliced transcript variants have been found for this gene.[provided by RefSeq, Jul 2011],

Function:Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further IKBA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation.,PTM:Phosphorylated; followed by degradation. Interaction with NKIRAS1 and NKIRAS2 probably prevents phosphorylation.,similarity:Belongs to the NF-kappa-B inhibitor family.,similarity:Contains 6 ANK repeats.,subunit:Interacts with THRB (via ligand-binding domain). Interacts with RELA and REL. Interacts with COMMD1 and inhibitor kappa B-interacting Ras-like NKIRAS1 and NKIRAS2.,tissue specificity:Expressed in all tissues examined.,

Cytoplasm . Nucleus .

Expressed in all tissues examined.

>>Chemokine signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>RIG-I-like receptor signaling pathway ;
>>Cytosolic DNA-sensing pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>Neurotrophin signaling pathway ;
>>Adipocytokine signaling pathway ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Leishmaniasis ;
>>Toxoplasmosis ;
>>Measles ;
>>Influenza A ;
>>Epstein-Barr virus infection ;
>>Coronavirus disease - COVID-19 ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer